Novo Nordisk’s amycretin, a next-generation amylin analog for obesity, demonstrated significant weight loss in a Phase 1/2 trial, with the highest 60 mg dose yielding average 24.3% weight reduction over 36 weeks versus placebo. However, overlapping weight-loss curves among lower doses and high adverse event rates complicate dose selection. These findings, presented at the American Diabetes Association conference and published in the Lancet, prompt questions about the optimal therapeutic window for amycretin amid its potent efficacy profile.